Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy.
Cancer Treat Rev
; 97: 102192, 2021 Jun.
Article
em En
| MEDLINE
| ID: mdl-33819755
ABSTRACT
Anti-programmed cell death protein 1 immunotherapy has become the new standard in the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). However, the population that benefits is small, warranting drug combinations and novel approaches. HNSCC is a profoundly immunosuppressive disease, characterized by the interplay among different immune regulatory pathways. As clinical trials evaluating immunotherapy combinations in patients with HNSCC have started producing preliminary results, preclinical evidence on potential new targets for combination immunotherapy continues to accumulate. This review summarizes emerging clinical and preclinical data on immunotherapy combinations for the treatment of HNSCC.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Receptor de Morte Celular Programada 1
/
Carcinoma de Células Escamosas de Cabeça e Pescoço
/
Inibidores de Checkpoint Imunológico
/
Neoplasias de Cabeça e Pescoço
/
Imunoterapia
Limite:
Humans
Idioma:
En
Revista:
Cancer Treat Rev
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Estados Unidos